Cancer Stem And Progenitor-like Cells As Pharmacological Targets In Breast Cancer Treatment.

dc.creatorde Souza, Valéria B
dc.creatorSchenka, André A
dc.date2015
dc.date2016-05-23T19:40:07Z
dc.date2016-05-23T19:40:07Z
dc.date.accessioned2018-03-29T01:27:41Z
dc.date.available2018-03-29T01:27:41Z
dc.identifierBreast Cancer : Basic And Clinical Research. v. 9, n. Suppl 2, p. 45-55, 2015.
dc.identifier1178-2234
dc.identifier10.4137/BCBCR.S29427
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/26609237
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/235207
dc.identifier26609237
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1303450
dc.descriptionThe present review is focused on the current role of neoplastic stem and progenitor-like cells as primary targets in the pharmacotherapy of cancer as well as in the development of new anticancer drugs. We begin by summarizing the main characteristics of these tumor-initiating cells and key concepts that support their participation in therapeutic failure. In particular, we discuss the differences between the major carcinogenesis models (ie, clonal evolution vs cancer stem cell (CSC) model) with emphasis on breast cancer (given its importance to the study of CSCs) and their implications for the development of new treatment strategies. In addition, we describe the main ways to target these cells, including the main signaling pathways that are more activated or altered in CSCs. Finally, we provide a comprehensive compilation of the most recently tested drugs.
dc.description9
dc.description45-55
dc.languageeng
dc.relationBreast Cancer : Basic And Clinical Research
dc.relationBreast Cancer (Auckl)
dc.rightsaberto
dc.sourcePubMed
dc.subjectAnticancer Drugs
dc.subjectBreast Cancer
dc.subjectCancer Stem Cell
dc.subjectStem Cell
dc.titleCancer Stem And Progenitor-like Cells As Pharmacological Targets In Breast Cancer Treatment.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución